EC
VERA icon

EntryPoint Capital’s Vera Therapeutics VERA Stock Holding History

EntryPoint Capital’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-455
Closed -$19.6K – 1652
2024
Q1 		$19.6K Sell
455
-208
-31% -$7.41K 0.02% 1097
2023
Q4 		$10.2K Buy
+663
New +$8.42K 0.01% 1154

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

EntryPoint Capital's VERA Position: Q2 2024 in Review

EntryPoint Capital sold out of Vera Therapeutics (VERA) in Q2 2024, closing a stake of 455 shares — an estimated $19.6K sold.

EntryPoint Capital first reported a position in VERA in Q4 2023 and held it in 2 quarters. The position peaked at $19.6K in Q1 2024. 171 funds tracked by Wall St. Rank hold VERA as of Q2 2024.

  • EntryPoint Capital reported no remaining Vera Therapeutics position as of Q2 2024 after selling out during the quarter.
  • EntryPoint Capital sold 455 Vera Therapeutics shares in Q2 2024, an estimated $19.6K.
  • EntryPoint Capital first reported a position in Vera Therapeutics in Q4 2023 and held it in 2 quarters.
  • EntryPoint Capital's Vera Therapeutics position peaked at $19.6K in Q1 2024.
  • 171 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.